Payment overview · 2025
General Payments
$2,417.72
133 reported records · 22 companies
Healthcare provider profile · identity verified
Chetna Mital
Allopathic & Osteopathic Physicians|Internal Medicine · HAMILTON, OH · NPI 1285637694
Verified facts
What the public records show
CMS Open Payments records show Chetna Mital received $2,417.72 in general payments during 2025 across 133 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $509.64 | 21.1% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $375.32 | 15.5% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $327.51 | 13.6% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.54 | 7.0% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.87 | 6.7% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $104.74 | 4.3% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.26 | 4.0% | 6 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $91.44 | 3.8% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.71 | 3.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.84 | 3.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.79 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.73 | 2.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $58.73 | 2.4% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.56 | 1.6% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $39.05 | 1.6% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $33.48 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.78 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.93 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.76 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.47 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.89 | 0.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.68 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,417.72 | 133 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $345.70 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $305.73 | 20 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $280.10 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $244.58 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $216.47 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $164.70 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $162.87 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $162.87 | 13 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.26 | 6 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $87.71 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.59 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $69.37 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $67.68 | 4 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $65.98 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.79 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $57.32 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.26 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.98 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.41 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $39.05 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 21 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 93 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 126 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
54 | 25 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2064 | 397 |
| Potassium Chloride | Potassium Chloride | 1001 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 879 | 161 |
| Furosemide | Furosemide | 846 | 168 |
| Lisinopril | Lisinopril | 834 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 802 | 174 |
| Pantoprazole Sodium | Pantoprazole Sodium | 790 | 167 |
| Gabapentin | Gabapentin | 623 | 131 |
| Metoprolol Succinate | Metoprolol Succinate | 582 | 115 |
| Metoprolol Tartrate | Metoprolol Tartrate | 523 | 124 |
| Donepezil Hcl | Donepezil Hcl | 502 | 72 |
| Eliquis | Apixaban | 446 | 94 |
| Sertraline Hcl | Sertraline Hcl | 429 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 398 | 80 |
| Trazodone Hcl | Trazodone Hcl | 385 | 75 |
| Memantine Hcl | Memantine Hcl | 380 | 57 |
| Omeprazole | Omeprazole | 369 | 90 |
| Clopidogrel | Clopidogrel Bisulfate | 361 | 75 |
| Losartan Potassium | Losartan Potassium | 319 | 82 |
| Metformin Hcl | Metformin Hcl | 313 | 76 |
| Buspirone Hcl | Buspirone Hcl | 310 | 72 |
| Mirtazapine | Mirtazapine | 308 | 58 |
| Oxycodone Hcl | Oxycodone Hcl | 297 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 294 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 126 |
| Montelukast Sodium | Montelukast Sodium | 264 | 67 |
| Carvedilol | Carvedilol | 259 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 56 |
| Famotidine | Famotidine | 209 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 37 |
| Spironolactone | Spironolactone | 201 | 49 |
| Simvastatin | Simvastatin | 196 | 40 |
| Allopurinol | Allopurinol | 183 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 180 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 172 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 170 | 19 |
| Jardiance | Empagliflozin | 166 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 165 | 50 |
| Alprazolam | Alprazolam | 159 | 21 |
| Midodrine Hcl | Midodrine Hcl | 158 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 43 |
| Ezetimibe | Ezetimibe | 153 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 152 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 142 | 72 |
| Divalproex Sodium | Divalproex Sodium | 139 | 24 |
| Ozempic | Semaglutide | 134 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 130 | 76 |
| Tramadol Hcl | Tramadol Hcl | 126 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 30 |
| Levetiracetam | Levetiracetam | 124 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 121 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 48 |
| Paroxetine Hcl | Paroxetine Hcl | 118 | 32 |
| Lorazepam | Lorazepam | 110 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 28 |
| Myrbetriq | Mirabegron | 108 | 23 |
| Pregabalin | Pregabalin | 108 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 105 | 70 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 104 | 42 |
| Ibuprofen | Ibuprofen | 103 | 53 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 70 |
| Warfarin Sodium | Warfarin Sodium | 100 | 12 |
| Finasteride | Finasteride | 96 | 21 |
| Tradjenta | Linagliptin | 96 | 28 |
| Gentamicin Sulfate | Gentamicin Sulfate | 95 | 28 |
| Baclofen | Baclofen | 94 | 17 |
| Farxiga | Dapagliflozin Propanediol | 93 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 23 |
| Latanoprost | Latanoprost | 91 | 16 |
| Sucralfate | Sucralfate | 91 | 26 |
| Xarelto | Rivaroxaban | 91 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 18 |
| Januvia | Sitagliptin Phosphate | 89 | 16 |
| Alendronate Sodium | Alendronate Sodium | 87 | 27 |
| Torsemide | Torsemide | 87 | 24 |
| Azithromycin | Azithromycin | 86 | 60 |
| Methocarbamol | Methocarbamol | 86 | 31 |
| Atenolol | Atenolol | 85 | 17 |
| Entresto | Sacubitril/Valsartan | 83 | 18 |
| Clonazepam | Clonazepam | 80 | suppressed |
| Prednisone | Prednisone | 79 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 78 | 35 |
| Levofloxacin | Levofloxacin | 77 | 53 |
| Clonidine Hcl | Clonidine Hcl | 76 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | 18 |
| Olanzapine | Olanzapine | 73 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | suppressed |
| Topiramate | Topiramate | 68 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 18 |
| Memantine Hcl Er | Memantine Hcl | 65 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 13 |
| Bupropion Xl | Bupropion Hcl | 59 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 15 |
| Admelog Solostar | Insulin Lispro | 57 | 13 |
| Aripiprazole | Aripiprazole | 56 | 11 |
| Nystatin | Nystatin | 56 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 19 |
| Risperidone | Risperidone | 54 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 54 | 25 |
| Valsartan | Valsartan | 53 | 12 |
| Acyclovir | Acyclovir | 52 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 52 | 35 |
| Nifedipine Er | Nifedipine | 52 | 14 |
| Cephalexin | Cephalexin | 51 | 38 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 48 | 11 |
| Vascepa | Icosapent Ethyl | 48 | 12 |
| Fenofibrate | Fenofibrate,micronized | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Bumetanide | Bumetanide | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 43 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 42 | suppressed |
| Oxycontin | Oxycodone Hcl | 42 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Scopolamine | Scopolamine | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 12 |
| Folic Acid | Folic Acid | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Trulicity | Dulaglutide | 34 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 33 | 11 |
| Gemtesa | Vibegron | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 24 |
| Glipizide | Glipizide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Klor-Con M20 | Potassium Chloride | 25 | 11 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 15 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | 17 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Daptomycin | Daptomycin | 21 | suppressed |
| Dulera | Mometasone/Formoterol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 20 | suppressed |
| Klayesta | Nystatin | 20 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Leflunomide | Leflunomide | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 14 |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Phenytoin | Phenytoin | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fycompa | Perampanel | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,417.72 · 133 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, CHARTIS CATHETER, Cologuard Collection Kit, FARXIGA, GARDASIL 9, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VOWST, Wegovy, XHANCE, ZENPEP, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error